NCT01610336 - A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment | Biotech Hunter

Enrollment

161

Participants

Timeline

Start Date

April 5, 2012

Primary Completion Date

June 10, 2016

Study Completion Date

May 27, 2020

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

INC280

During Phase Ib, INC280 was taken at escalating doses. During Phase II part, INC280 was taken at recommended Phase II dose.

DRUG

Gefitinib

Gefitinib 250 mg taken once daily

Trial Locations (31)

3000

Novartis Investigative Site, Leuven

3165

Novartis Investigative Site, East Bentleigh

4102

Novartis Investigative Site, Woolloongabba

5800

Novartis Investigative Site, Maastricht

10002

Novartis Investigative Site, Taipei

10400

Novartis Investigative Site, Bangkok

10408

Novartis Investigative Site, Gyeonggi-do

20133

Novartis Investigative Site, Milan

20141

Novartis Investigative Site, Milan

28034

Novartis Investigative Site, Madrid

31059

Novartis Investigative Site, Toulouse

41124

Novartis Investigative Site, Modena

51000

Novartis Investigative Site, Guangzhou

52621

Novartis Investigative Site, Ramat Gan

60590

Novartis Investigative Site, Frankfurt

67091

Novartis Investigative Site, Strasbourg

70403

Novartis Investigative Site, Tainan City

79106

Novartis Investigative Site, Freiburg im Breisgau

100039

Novartis Investigative Site, Beijing

169610

Novartis Investigative Site, Singapore

200433

Novartis Investigative Site, Shanghai

510060

Novartis Investigative Site, Guangzhou

Unknown

Novartis Investigative Site, Auckland

135 8550

Novartis Investigative Site, Koto Ku

1066 CX

Novartis Investigative Site, Amsterdam

3015 GD

Novartis Investigative Site, Rotterdam

05505

Novartis Investigative Site, Seoul

06591

Novartis Investigative Site, Seoul

03080

Novartis Investigative Site, Seoul

06351

Novartis Investigative Site, Seoul

08035

Novartis Investigative Site, Barcelona